Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

38
SUPERVALU (SVU) Q1 Earnings: Will Retail Unit Remain a Drag?

4h zacks
SUPERVALU INC. (SVU - Free Report) is scheduled to release first-quarter fiscal 2019 results on Jul 26. The company has been battling softness at its retail segment for quite some time, owing to intense competition and increased promotional activities. Though concentration on strengthening wholesale business remains a driving factor, sluggish retail business remains a concern for SUPERVALU that delivered a negative earnings surprise in the last reported quarter.
BHI SVU GEC GE TFM GES GNE

10
SVU / Supervalu, Inc. DEFINITIVE ADDITIONAL MATERIALS

2018-07-19 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SVU

10
SVU / Supervalu, Inc. DEFA14A

2018-07-18 sec.gov
Document UNITED STATES
SVU

10
SVU / Supervalu, Inc. DEFA14A

2018-07-17 sec.gov
Document UNITED STATES
SVU

13
Hidden Value In SuperValu

2018-07-17 seekingalpha
SuperValu’s current market capitalization reflects only a fraction of its sum-of-the-parts value, indicating a strong asymmetric risk/reward opportunity.
SYY SVU UNFI

10
SVU / Supervalu, Inc. DEFA14A

2018-07-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SVU

9
SVU / Supervalu, Inc. DEFC14A

2018-07-02 sec.gov
Document Table of Contents UNITED STATES<
SVU

50
The #1 Retail REIT Best Prepared To Battle Amazon

2018-07-02 seekingalpha
AMZN proved what most REIT management teams have been saying for some time, that successful retailers have to pursue an Omni-channel strategy and real estate is key.
REG BRK.A REG.PRG SVU XKE REG.PRF KR

13
SVU / Supervalu, Inc. DEFINITIVE PROXY STATEMENT

2018-06-29 sec.gov
@@ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SVU

10
SVU / Supervalu, Inc. REVISED PRELIMINARY PROXY STATEMENT

2018-06-27 sec.gov
@@ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SVU

10
SVU / Supervalu, Inc. REVISED PRELIMINARY PROXY STATEMENT

2018-06-27 sec.gov
@@ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SVU

8
SVU / Supervalu, Inc. PRER14A

2018-06-26 sec.gov
Document Table of Contents UNITED STATES<
SVU

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Silicon Investor Message Boards

This table lists all message boards related to SVU / Supervalu, Inc. on message board site Silicon Investor.

SVU, excellent fertilizer stock Spur ventures SVU VSE
CUSIP: 868536103